KLI

Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis

Metadata Downloads
Abstract
Background Regorafenib has been shown to improve clinical outcomes compared to placebo, becoming a standard second-line therapy for sorafenib-progressed and -tolerated hepatocellular carcinoma (HCC) patients. Objective We performed a multicentre, retrospective study in Italy and Korea to evaluate the effectiveness of the treatment sequence sorafenib-regorafenib compared with sorafenib and physician's choice in a real-life setting. Patients and Methods A propensity score model was developed to control the results for baseline variable imbalances between the arm treated with sorafenib and regorafenib (S-R) and the arm treated with sorafenib and physician's choice (S-P). Survival analysis was conducted on the matched population. Results After the application of propensity score matching, we analysed 99 patients in the arm treated with S-R and 99 patients in the arm treated with S-P. For the S-R group, the median overall survival was 22.2 months (95% CI 17.1-27.4), compared to 17.9 months (95% CI 15.1-50.0) for the S-P group. The results of the univariate analysis showed a 31% reduction of death risk for patients treated with S-R (p = 0.0382) compared to patients treated with S-P. Interaction tests highlighted the predictive role of alpha-fetoprotein (AFP), neutrophil-to-lymphocyte ratio (NLR), and extrahepatic spread. Conclusion This study provides additional proof of the superiority of the S-R treatment over the S-P treatment approach in advanced HCC patients from a real-life setting.
Author(s)
김형돈류백렬박숙련방영학유민희유창훈Andrea Casadei-GardiniCaterina VivaldiFrancesca SalaniGiovanni Luca FrassinetiIlario Giovanni RapposelliMargherita RiminiMario Domenico RizzatoMario ScartozziMartina ValgiustiSara LonardiStefano CascinuValentina BurgioValentina MassaVittorina Za
Issued Date
2021
Type
Article
Keyword
AnalysisBiomedicineClinical outcomesgeneralLiver cancerMedicineMedicine & Public HealthOncologyOriginal Research ArticlePhysiciansSurvival analysisTargeted cancer therapy
DOI
10.1007/s11523-021-00797-3
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7962
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2494875769&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Sequential%20Treatment%20of%20Sorafenib-Regorafenib%20Versus%20Sorafenib-Physician%27s%20Choice:%20A%20Propensity%20Score-Matched%20Analysis&offset=0&pcAvailability=true
Publisher
TARGETED ONCOLOGY
Location
미국
Language
영어
ISSN
1776-2596
Citation Volume
16
Citation Number
3
Citation Start Page
401
Citation End Page
410
Appears in Collections:
Medicine > Medicine
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.